Study #2024-0517
A phase II, single-center, single-arm study evaluating the safety and efficacy of Golidocitinib in the management of newly diagnosed peripheral T cell lymphoma patients (GOLDEN Study) and correlative study
MD Anderson Study Status
Enrolling
Treatment Agent
Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Description
To learn if the study drug golidocitinib given alone or in combination with the standard drug combination therapy called CHOP can help to control PTCL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Peripheral T Cell Lymphoma
Study phase:
Phase II
Physician name:
Luis Malpica Castillo
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-955-5036
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.